View by Specialty

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

Lupus News

SPONSORED CONTENT
Save
SPONSORED CONTENT
August 12, 2024
1 min read
Save

FDA approves IND application for Eque-cel T-cell therapy in SLE, lupus nephritis

FDA approves IND application for Eque-cel T-cell therapy in SLE, lupus nephritis

The FDA has approved an investigational new drug application for Eque-cel, an autologous T-cell injection, in patients with systemic lupus erythematosus and lupus nephritis, according to a press release from the manufacturer.

SPONSORED CONTENT
August 07, 2024
2 min read
Save

Renal, cardiovascular risks lower in patients with lupus using metformin

Renal, cardiovascular risks lower in patients with lupus using metformin

Metformin may protect against the progression of adverse renal and cardiovascular outcomes in patients systemic lupus erythematosus, including lupus nephritis and infarction, according to data published in ACR Open Rheumatology.

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

SPONSORED CONTENT
August 02, 2024
6 min read
Save

IFN signature in lupus endotypes may lead to ‘targeted and personalized’ treatments

IFN signature in lupus endotypes may lead to ‘targeted and personalized’ treatments

Specific interferon signatures may influence the symptoms and severity of systemic lupus erythematosus, with various interferon types potentially “contributing to distinct pathogenic processes,” according to recent findings.

SPONSORED CONTENT
July 31, 2024
2 min read
Save

Understanding lupus processes helps identify ‘important targets’ for intervention

Understanding lupus processes helps identify ‘important targets’ for intervention

Ongoing research into the disease processes of lupus has yielded an increased number of therapeutic targets, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.

SPONSORED CONTENT
July 30, 2024
3 min read
Save

Though common in rheumatology, lymphadenopathy may be ‘hallmark’ of serious, rare disease

Although swollen lymph nodes are often common in rheumatology, they are also a “hallmark” of rare, life-threatening diseases, such as IgG4-related disease and Castleman disease, according to data published in Rheumatology.

SPONSORED CONTENT
July 29, 2024
2 min read
Save

Diabetes, weight loss drugs emerging as treatment pathway in rheumatology

Diabetes, weight loss drugs emerging as treatment pathway in rheumatology

Drugs used to treat diabetes and obesity, such as GLP-1 receptor agonists, are becoming an important treatment pathway in rheumatology, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.

SPONSORED CONTENT
July 22, 2024
3 min read
Save

CAR T cells one year later: What have we learned?

CAR T cells one year later: What have we learned?

Nearly 1 year ago, I wrote my first editorial about the emergence and excitement surrounding the early experience with CAR T cells — CAR T Cells in Autoimmunity: A Potential Therapy About to Explode.

SPONSORED CONTENT
July 22, 2024
13 min read
Save

CAR T-cell therapy may be a ‘miracle,’ but it is too soon to say ‘cure’

CAR T-cell therapy may be a ‘miracle,’ but it is too soon to say ‘cure’

It has been at least 2 years since the first cohort of patients with lupus underwent chimeric antigen receptor T-cell treatment, and, at least so far, for every one of them, each new dawn represents another day spent in full remission.

SPONSORED CONTENT
July 17, 2024
8 min read
Save

Monitoring nightmares, hallucinations ‘extremely valuable’ in lupus, early flare treatment

Monitoring nightmares, hallucinations ‘extremely valuable’ in lupus, early flare treatment

Nightmares and hallucinations may occur at any stage of disease course in patients with systemic lupus erythematosus, according to recent findings.

SPONSORED CONTENT
July 15, 2024
2 min read
Save

SGLT2 inhibitors slash risks for lupus nephritis, heart failure in SLE, type 2 diabetes

SGLT2 inhibitors slash risks for lupus nephritis, heart failure in SLE, type 2 diabetes

Treatment with sodium-glucose cotransporter-2 inhibitors significantly lowered risks for lupus nephritis, dialysis and kidney transplant for patients with systemic lupus erythematosus and type 2 diabetes, according to data.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails